Manual for Ibogaine Therapy: Screening, Safety, Monitoring & Aftercare

Lotsof, Howard S., Wachtel, Boaz, Emery, Marc, Frenken, Geerte, Glatt, Sara, Mariano, Brian, Naeher, Karl, Polanko, Martin, Resinovic, Marko, Sandberg, Nick, Taub, Eric, Waizmann, Samuel, Wells, Hattie · 2003

AI-extracted · unverified · confirm at source

Foundational treatment manual establishing 15-20 mg/kg dosing, 48-hour monitoring, EKG screening, and inclusion/exclusion criteria that shaped all subsequent ibogaine protocols

Dosing: 15–20 mg/kg therapeutic; 2 mg/kg test dose; 25–300 mg/day low-dose (oral)

Safety data present: ELECTROLYTE

Contraindications: Significant cardiac artery blockage or history of myocardial infarction, Blood pressure >170/105 or <80/60; pulse >120 or <50 bpm, Uncontrolled hypertension, Concurrent drug use during treatment (potentiates opiate/stimulant toxicity), Active neurological or psychiatric disorders requiring treatment, Beck Depression Inventory score ≥24 (debated by contributing authors), Concomitant medications causing adverse interactions (anti-epileptics, antidepressants, neuroleptics), History of sensitivity or adverse reaction to ibogaine, Clinically significant abnormal laboratory values, GI, liver, or kidney disease compromising metabolism/excretion, Active peptic ulcer (nonfatal adverse events documented), Active tuberculosis, Pregnancy, Liver enzymes >400% above normal (NIDA threshold)